NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-.

Cover of StatPearls

StatPearls [Internet].

Show details

Paroxysmal Supraventricular (PSVT)

; .

Author Information

Last Update: May 14, 2019.

Introduction

Atrioventricular node (AV) measures approximately 1 by 3 by 5  millimeters and sits within an anatomic region bordered anteriorly by septal tricuspid valve annulus, superiorly by the tendon of Todaro and posteriorly by the coronary sinus ostium. This anatomic region is also commonly referred to as the triangle of Koch. AV node is a subendocardial structure located in the inferior-posterior right atrium. The blood supply to the AV node is from the AV nodal branch of the right coronary artery  (90%) or the left circumflex artery (10%) depending on right or left dominant blood supply to the heart. The first septal perforator of the left anterior descending artery also supplies blood to the AV node.[1][2][3][4][5]

Paroxysmal supraventricular tachycardia (PSVT) accounts for intermittent episodes of supraventricular tachycardia with sudden onset and termination. PSVT is part of the narrow QRS complex tachycardias with a regular ventricular response in contrast to multifocal atrial tachycardia, atrial fibrillation, and atrial flutter. SVTs are classified based on the origin of the rhythm and whether the rhythm is regular or irregular.[6][7][8][9][10][11]

Atrial in origin and regular rhythm:

  • Sinus tachycardia
  • Inappropriate sinus tachycardia
  • Sinoatrial nodal reentrant tachycardia
  • Atrial flutter
  • Atrial fibrillation

Atrial in origin and irregular rhythm:

  • Multifocal atrial tachycardia
  • Atrial flutter with variable block
  • Atrial fibrillation

AV node in origin and regular rhythm:

  • Junctional tachycardia 
  • Atrioventricular nodal reentrant tachycardia
  • Atrioventricular reentrant tachycardia

AV node in origin and irregular rhythm:

  • None

Etiology

Numerous conditions and medications can lead to PSVT in patients. [6][12][13][14]

Some of these conditions and medications are listed below:

  • Hyperthyroidism
  • Caffeinated beverages
  • Nicotine
  • Hydralazine
  • Atropine
  • Adenosine
  • Verapamil
  • Salbutamol
  • Ecstasy
  • Cocaine
  • Amphetamines
  • Alcohol 
  • Digoxin toxicity
  • Myocardial infarction
  • Structural heart disease
  • Ebstein anomaly
  • Pericarditis
  • Myocarditis
  • Cardiomyopathy
  • Pulmonary embolism
  • Rheumatic heart disease
  • Mitral valve prolapse
  • Pneumonia
  • Chronic lung disease
  • Chest wall trauma
  • Anxiety
  • Hypovolemia
  • Hypoxia

Epidemiology

In the United States, the prevalence of PSVT is approximately 0.2%, and it has an incidence of one to three cases every thousand patients. The most common of the PSVT is atrial fibrillation with a prevalence rate of approximately 0.4% to 1% occurring in men and women equally, it is projected to affect as many as 7.5 million patients by 2050. The risk of developing PSVT was found to be twice in women as compared to men in a population-based study, with the prevalence of the PSVT higher with age. Atrioventricular nodal reentrant tachycardia is found more commonly in patients who are middle-aged or older. Whereas, PSVT with an accessory pathway is most common in adolescents and their occurrence decreases with age.[15][16][17]

Pathophysiology

PSVT is often due to different reentry circuits in the heart, where less frequent causes include enhanced or abnormal automaticity and triggered activity. Reentry circuits include a pathway within and around the sinus node, within the atrial myocardium, within the atrioventricular node or an accessory pathway involving the atrioventricular node.[18][19][20] Different types of PSVT result depending on the existing circuits, and examples are:

  • Sinus node: Sinoatrial node reentrant tachycardia
  • Atrial myocardium: Atrial flutter, atrial fibrillation, and multifocal atrial tachycardia
  • Atrioventricular node: Atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia

Histopathology

Under most circumstance, careful examination in patients with PSVT will show reentry circuits discussed above. No specific histopathologic findings are found in patients with PSVTs secondary to triggered activity and enhanced or abnormal automaticity.[20]

History and Physical

The severity of symptoms in patients with PSVT depends on any underlying structural heart disease, the frequency of PSVT episodes and the patient's hemodynamic reserve. Usually patients with PSVT present with symptoms of dizziness, syncope, nausea, shortness of breath, intermittent palpitations, pain/discomfort in the neck, pain/discomfort in the chest, anxiety, fatigue, diaphoresis, and polyuria secondary atrial natriuretic factor secreted mainly by the heart's atria in response to atrial stretch. Most common symptoms are dizziness and palpitations. Patients with PSVT and known history of coronary artery disease may present with a myocardial infarction secondary to the stress on the heart. Patients with PSVT and known history of heart failure may come in with acute exacerbation. Frequent PSVTs in a patient can result in new-onset of heart failure secondary to tachycardia-induced cardiomyopathy.[21]

A detailed history of the patient with PSVT should include past medical and cardiac history, time of symptom onset, prior episodes, and treatments. Patients' current medication list must be obtained. Investigations of involvement in physical activities such as exercise or outdoor sports should be made, as patients who have symptomatic PSVT's avoid such hobbies. Patients presenting with PSVTs should get a thorough physical exam including vital signs (respiratory rate, blood pressure, temperature, and heart rate) to help assess their hemodynamic stability.[22]

Evaluation

A significant component of evaluation for a patient who presents with signs and symptoms of PSVT is history and physical exam. These should include vital signs (respiratory rate, blood pressure, temperature, and heart rate), review of the patient's medication list and a 12-lead electrocardiogram. During an evaluation, a health care provider should establish if the patient is hemodynamically stable and whether they have any underlying ischemic heart disease or heart failure. A healthcare provider should consider thyroid function testing, pulmonary function testing, including routine blood work, and echocardiography as part of their initial evaluation of patients presenting with symptomatic PSVTs.[23][24]

Treatment / Management

Treatment of PSVT in a patient is dependent on the type of rhythm present on the electrocardiogram and the patient's hemodynamic stability. Patients presenting with hypotension, shortness of breath, chest pain, shock, or altered mental status are considered hemodynamically unstable, and their electrocardiogram evaluation must be done to determine if they are in sinus rhythm or not. If they are not in sinus rhythm, these patients should undergo urgent cardioversion. If they are determined to be in an appropriate sinus tachycardia than their underlying etiology must be treated, and for any manifestations of cardiac ischemia intravenous beta-blockers should be considered. If they have inappropriate sinus tachycardia on the electrocardiogram and are determined to be hemodynamically unstable, treatment with intravenous beta-blockers may be appropriate.[25][26][27]

If on initial evaluation, a patient is to found to be hemodynamically stable, then the treatment of the patient depends on the specific PSVT present on the electrocardiogram. If the 12-lead electrocardiogram shows that the rhythm is irregular and P waves are absent, then the patient should be appropriately treated for atrial fibrillation. If the rhythm on the electrocardiogram is irregular and flutter waves are present, then the patient should be treated for atrial flutter. If the rhythm on the electrocardiogram is irregular and multiple P wave morphologies are present, then the patient should be treated for multifocal atrial tachycardia.[28]

In patients who are hemodynamically stable and showing a regular rhythm with visible P waves on the electrocardiogram, then an assessment of the atrial rate, the relationship between the atrial and ventricular pacing, P-wave morphology and the P-wave position in the rhythm cycle is required. Type of PSVT present (atrial tachycardia, multifocal atrial tachycardia, atrial flutter, atrial flutter with a variable block, intra-atrial reentrant tachycardia, sinus tachycardia, sinoatrial node reentrant tachycardia, atrioventricular nodal reentrant tachycardia, atrioventricular reciprocating tachycardia, junctional ectopic tachycardia, and nonparoxysmal junctional tachycardia) determines the treatment.[29][30]

In patients who are hemodynamically stable and have electrocardiogram that shows a regular rhythm with undetectable P waves, Valsalva maneuvers, carotid sinus massage, or intravenous adenosine might be used to slow the ventricular rate or convert the rhythm into sinus rhythm and thus aid in the diagnosis. In some instances, increasing the electrocardiogram paper speed from 25 mm per second to 50 mm per second might help as well. If intravenous adenosine does not work, then intravenous or oral calcium channel blockers or beta-blockers should be used. Patients with PSVTs must also undergo evaluation for any underlying pre-excitation syndrome, and patients who fail medical treatment or those who might need radiofrequency catheter ablation need cardiology consultation.[31][32][33]

Differential Diagnosis

As below[34][35]:

  • Atrial tachycardia
  • Multifocal atrial tachycardia (MAT)
  • Atrial flutter
  • Atrial flutter with variable block
  • Atrial fibrillation
  • Intraatrial reentrant tachycardia
  • Sinus tachycardia
  • Inappropriate sinus tachycardia
  • Sinoatrial node reentrant tachycardia
  • Atrioventricular nodal reentrant tachycardia
  • Atrioventricular reciprocating (reentrant) tachycardia
  • Junctional ectopic tachycardia
  • Nonparoxysmal junctional tachycardia

Prognosis

In cases with no structural heart disease, the prognosis of PSVT is reasonably good.

Complications

If not identified promptly symptomatic complications such as syncope, fatigue or dizziness can occur. 

Deterrence and Patient Education

Educating patients at risk for this rhythm and making a closed loop communication between them and their providers can help further improve the management of these rhythms.

Pearls and Other Issues

Frequent PSVT can result in tachycardia-induced cardiomyopathy, a study on pregnant females found that PSVT in the first to second gestational month increase the chances of the child developing ostium secundum atrial septal defect.

Enhancing Healthcare Team Outcomes

If available patient education should be provided using resources familiar to the patient including online resources and pamphlets. 

Questions

To access free multiple choice questions on this topic, click here.

References

1.
Van der Hauwaert LG, Stroobandt R, Verhaeghe L. Arterial blood supply of the atrioventricular node and main bundle. Br Heart J. 1972 Oct;34(10):1045-51. [PMC free article: PMC458545] [PubMed: 5086972]
2.
Pejković B, Krajnc I, Anderhuber F, Kosutić D. Anatomical aspects of the arterial blood supply to the sinoatrial and atrioventricular nodes of the human heart. J. Int. Med. Res. 2008 Jul-Aug;36(4):691-8. [PubMed: 18652764]
3.
Saremi F, Abolhoda A, Ashikyan O, Milliken JC, Narula J, Gurudevan SV, Kaushal K, Raney A. Arterial supply to sinuatrial and atrioventricular nodes: imaging with multidetector CT. Radiology. 2008 Jan;246(1):99-107; discussion 108-9. [PubMed: 18024438]
4.
Sumitomo N, Tateno S, Nakamura Y, Ushinohama H, Taniguchi K, Ichikawa R, Fukuhara J, Abe O, Miyashita M, Kanamaru H, Ayusawa M, Harada K, Mugishima H. Clinical importance of Koch's triangle size in children: a study using 3-dimensional electroanatomical mapping. Circ. J. 2007 Dec;71(12):1918-21. [PubMed: 18037746]
5.
Inoue S, Becker AE. Koch's triangle sized up: anatomical landmarks in perspective of catheter ablation procedures. Pacing Clin Electrophysiol. 1998 Aug;21(8):1553-8. [PubMed: 9725153]
6.
Ganz LI, Friedman PL. Supraventricular tachycardia. N. Engl. J. Med. 1995 Jan 19;332(3):162-73. [PubMed: 7800009]
7.
Blomström-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ, Campbell WB, Haines DE, Kuck KH, Lerman BB, Miller DD, Shaeffer CW, Stevenson WG, Tomaselli GF, Antman EM, Smith SC, Alpert JS, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Hiratzka LF, Hunt SA, Jacobs AK, Russell RO, Priori SG, Blanc JJ, Budaj A, Burgos EF, Cowie M, Deckers JW, Garcia MA, Klein WW, Lekakis J, Lindahl B, Mazzotta G, Morais JC, Oto A, Smiseth O, Trappe HJ., American College of Cardiology. American Heart Association Task Force on Practice Guidelines. European Society of Cardiology Committee for Practice Guidelines. Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias). Circulation. 2003 Oct 14;108(15):1871-909. [PubMed: 14557344]
8.
Fox DJ, Tischenko A, Krahn AD, Skanes AC, Gula LJ, Yee RK, Klein GJ. Supraventricular tachycardia: diagnosis and management. Mayo Clin. Proc. 2008 Dec;83(12):1400-11. [PubMed: 19046562]
9.
Katritsis DG, Josephson ME. Differential diagnosis of regular, narrow-QRS tachycardias. Heart Rhythm. 2015 Jul;12(7):1667-76. [PubMed: 25828600]
10.
Orejarena LA, Vidaillet H, DeStefano F, Nordstrom DL, Vierkant RA, Smith PN, Hayes JJ. Paroxysmal supraventricular tachycardia in the general population. J. Am. Coll. Cardiol. 1998 Jan;31(1):150-7. [PubMed: 9426034]
11.
Ferguson JD, DiMarco JP. Contemporary management of paroxysmal supraventricular tachycardia. Circulation. 2003 Mar 04;107(8):1096-9. [PubMed: 12615783]
12.
Trohman RG. Supraventricular tachycardia: implications for the intensivist. Crit. Care Med. 2000 Oct;28(10 Suppl):N129-35. [PubMed: 11055681]
13.
Kalbfleisch SJ, el-Atassi R, Calkins H, Langberg JJ, Morady F. Differentiation of paroxysmal narrow QRS complex tachycardias using the 12-lead electrocardiogram. J. Am. Coll. Cardiol. 1993 Jan;21(1):85-9. [PubMed: 8417081]
14.
Accardi AJ, Miller R, Holmes JF. Enhanced diagnosis of narrow complex tachycardias with increased electrocardiograph speed. J Emerg Med. 2002 Feb;22(2):123-6. [PubMed: 11858914]
15.
Link MS. Clinical practice. Evaluation and initial treatment of supraventricular tachycardia. N. Engl. J. Med. 2012 Oct 11;367(15):1438-48. [PubMed: 23050527]
16.
Smith GD, Dyson K, Taylor D, Morgans A, Cantwell K. Effectiveness of the Valsalva Manoeuvre for reversion of supraventricular tachycardia. Cochrane Database Syst Rev. 2013 Mar 28;(3):CD009502. [PubMed: 23543578]
17.
Chauhan VS, Krahn AD, Klein GJ, Skanes AC, Yee R. Supraventricular tachycardia. Med. Clin. North Am. 2001 Mar;85(2):193-223, ix. [PubMed: 11233946]
18.
Akhtar M, Jazayeri MR, Sra J, Blanck Z, Deshpande S, Dhala A. Atrioventricular nodal reentry. Clinical, electrophysiological, and therapeutic considerations. Circulation. 1993 Jul;88(1):282-95. [PubMed: 8319342]
19.
Rosen KM, Mehta A, Miller RA. Demonstration of dual atrioventricular nodal pathways in man. Am. J. Cardiol. 1974 Feb;33(2):291-4. [PubMed: 4810028]
20.
Waldo AL, Wit AL. Mechanisms of cardiac arrhythmias. Lancet. 1993 May 08;341(8854):1189-93. [PubMed: 8098085]
21.
Klein GJ, Sharma AD, Yee R, Guiraudon GM. Classification of supraventricular tachycardias. Am. J. Cardiol. 1987 Aug 31;60(6):27D-31D. [PubMed: 3630922]
22.
Basta M, Klein GJ, Yee R, Krahn A, Lee J. Current role of pharmacologic therapy for patients with paroxysmal supraventricular tachycardia. Cardiol Clin. 1997 Nov;15(4):587-97. [PubMed: 9403162]
23.
Xie B, Thakur RK, Shah CP, Hoon VK. Clinical differentiation of narrow QRS complex tachycardias. Emerg. Med. Clin. North Am. 1998 May;16(2):295-330. [PubMed: 9621846]
24.
Krahn AD, Yee R, Klein GJ, Morillo C. Inappropriate sinus tachycardia: evaluation and therapy. J. Cardiovasc. Electrophysiol. 1995 Dec;6(12):1124-8. [PubMed: 8720214]
25.
Brugada P, Wellens HJ. The role of triggered activity in clinical ventricular arrhythmias. Pacing Clin Electrophysiol. 1984 Mar;7(2):260-71. [PubMed: 6200854]
26.
Lesh MD, Van Hare GF, Epstein LM, Fitzpatrick AP, Scheinman MM, Lee RJ, Kwasman MA, Grogin HR, Griffin JC. Radiofrequency catheter ablation of atrial arrhythmias. Results and mechanisms. Circulation. 1994 Mar;89(3):1074-89. [PubMed: 8124793]
27.
Josephson ME, Kastor JA. Supraventricular tachycardia: mechanisms and management. Ann. Intern. Med. 1977 Sep;87(3):346-58. [PubMed: 332025]
28.
Josephson ME, Wellens HJ. Electrophysiologic evaluation of supraventricular tachycardia. Cardiol Clin. 1997 Nov;15(4):567-86. [PubMed: 9403161]
29.
Murdock CJ, Leitch JW, Teo WS, Sharma AD, Yee R, Klein GJ. Characteristics of accessory pathways exhibiting decremental conduction. Am. J. Cardiol. 1991 Mar 01;67(6):506-10. [PubMed: 1998282]
30.
Obel OA, Camm AJ. Supraventricular tachycardia. ECG diagnosis and anatomy. Eur. Heart J. 1997 May;18 Suppl C:C2-11. [PubMed: 9152669]
31.
Pieper SJ, Stanton MS. Narrow QRS complex tachycardias. Mayo Clin. Proc. 1995 Apr;70(4):371-5. [PubMed: 7898144]
32.
Porter MJ, Morton JB, Denman R, Lin AC, Tierney S, Santucci PA, Cai JJ, Madsen N, Wilber DJ. Influence of age and gender on the mechanism of supraventricular tachycardia. Heart Rhythm. 2004 Oct;1(4):393-6. [PubMed: 15851189]
33.
Tada H, Oral H, Greenstein R, Pelosi F, Knight BP, Strickberger SA, Morady F. Analysis of age of onset of accessory pathway-mediated tachycardia in men and women. Am. J. Cardiol. 2002 Feb 15;89(4):470-1. [PubMed: 11835934]
34.
Lévy S, Ricard P. Using the right drug: a treatment algorithm for regular supraventricular tachycardias. Eur. Heart J. 1997 May;18 Suppl C:C27-32. [PubMed: 9152672]
35.
Shaker H, Jahanian F, Fathi M, Zare M. Oral verapamil in paroxysmal supraventricular tachycardia recurrence control: a randomized clinical trial. Ther Adv Cardiovasc Dis. 2015 Feb;9(1):4-9. [PubMed: 25297337]
Copyright © 2019, StatPearls Publishing LLC.

This book is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, a link is provided to the Creative Commons license, and any changes made are indicated.

Bookshelf ID: NBK507699PMID: 29939521

Views

  • PubReader
  • Print View
  • Cite this Page

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...